Sarepta Therapeutics (SRPT) Total Current Liabilities (2010 - 2026)

Sarepta Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $499.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 17.57% year-over-year to $499.2 million; the trailing twelve-month figure through Mar 2026 stood at $499.2 million (down 17.57% YoY), and the FY2025 full-year result was $1.1 billion, up 49.69% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $499.2 million, down from $1.1 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $1.1 billion in Q4 2025, with the low at $450.7 million in Q3 2023.
• Average Total Current Liabilities over 5 years is $654.9 million, with a median of $608.7 million recorded in 2024.
• Year-over-year, Total Current Liabilities soared 61.45% in 2022 and fell 25.24% in 2023.
• Tracing SRPT's Total Current Liabilities over 5 years: stood at $619.6 million in 2022, then gained by 5.5% to $653.7 million in 2023, then advanced by 11.94% to $731.7 million in 2024, then surged by 49.69% to $1.1 billion in 2025, then tumbled by 54.43% to $499.2 million in 2026.
• The last three Total Current Liabilities figures came in at $499.2 million (Q1 2026), $1.1 billion (Q4 2025), and $921.4 million (Q3 2025), per Business Quant data.

Peer Comparison